Prosecution Insights
Last updated: October 26, 2026

Robert H Havlin, USPTO Patent Examiner

Listed by the USPTO as HAVLIN, ROBERT H

Tech Center 1600 • Art Units: 1622 1626 1639 1675 1692

This examiner grants 51% of resolved cases

Analysis

HAVLIN, ROBERT H works in tech center 1600 and art unit 1622. The record covers 1054 resolved cases, with an allowance rate of 51.3% and a median of 1031 days to allowance. The interview lift is 28.3%, indicating a positive association that may help applicants address examination issues despite the moderate allowance rate.

The leading companies are ThermoLife International LLC, Boehringer Ingelheim International GmbH, and University of Washington. The principal firms are BOOTH UDALL, PLC, CANTOR COLBURN LLP, and FOLEY & LARDNER LLP. The substantial case volume supports using these figures as meaningful context for prosecution planning.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

51.3%
Allow Rate
-8.7% vs TC avg
1,163
Total Applications
+28.3%
Interview Lift
1031
Avg Prosecution Days
Based on 1054 resolved cases, 2023–2026

Rejection Statute Breakdown

1.6%
§101 Eligibility
25.3%
§102 Novelty
30.9%
§103 Obviousness
28.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18435115 METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS Final Rejection ANTECIP BIOVENTURES II LLC
18589552 New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases Non-Final OA Boehringer Ingelheim International GmbH
18585280 New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases Non-Final OA Boehringer Ingelheim International GmbH
17653897 FEATURIZATION OF CARBON DIOXIDE CAPTURE CHARACTERISTICS IN MOLECULES Non-Final OA INTERNATIONAL BUSINESS MACHINES CORPORATION
18058216 METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING Final Rejection Becton, Dickinson and Company
18872978 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING DEMETHYLZEYLASTERAL Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18173386 NUCLEIC ACID EXTRACTION AND AMPLIFICATION CONTROLS AND METHODS OF USE THEREOF Final Rejection LIFE TECHNOLOGIES CORPORATION
18006681 PROCESS FOR PRODUCING A GAS STREAM COMPRISING CARBON MONOXIDE Final Rejection JOHNSON MATTHEY DAVY TECHNOLOGIES LIMITED
18562205 ORGANIC ELECTROLUMINESCENT MATERIALS CONTAINING B-N FUSED RINGS, AND APPLICATIONS THEREOF Non-Final OA GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Robert H Havlin's allowance rate?

51.3% of resolved applications examined by Robert H Havlin were allowed (1,054 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.

Does an interview help with examiner Robert H Havlin?

This examiner's interview lift is +28.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Robert H Havlin take to allow a patent?

Applications allowed by Robert H Havlin took 1,031 days on average from filing to allowance.

Which art unit does examiner Robert H Havlin work in?

Robert H Havlin examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month